Bavarian Nordic A/S

ISIN DK0015998017

 | 

WKN 917165

Market cap (in EUR)
1,760.09 m
Country
Denmark
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Denmark

Financials

Key metrics

Market capitalisation, EUR 1,760.09 m
EPS, EUR 2.26
P/B ratio 1.12
P/E ratio 9.88
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 765.85 m
Net income, EUR 132.50 m
Profit margin 17.30%

What ETF is Bavarian Nordic A/S in?

There are 31 ETFs which contain Bavarian Nordic A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Bavarian Nordic A/S is the Xtrackers Nordic Net Zero Pathway Paris Aligned UCITS ETF 1C.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.